All-trans retinoic acid (ATRA) induces complete remission in patients with acute promyelocytic leukemia (APL). However, ATRA sometimes causes retinoic acid syndrome (RAS) characterized by respiratory distress, pleural effusions, fever and weight gain. To investigate the pathophysiology of RAS, we generated an animal model by injecting an APL cell line, NB4, into immunodeficient mice. When NOD/scid mice were injected intravenously with fully differentiated NB4 cells (1 Â 10 7 ) and then given a daily administration of ATRA, three of 12 mice died of pulmonary edema within 14 days. Pathologically, dilated lung capillary vessels and alveolar effusions were observed. After the injection, NB4 cells were detected in the lung within 2 days and in the pleural effusion later on. The gene expression levels of CXC chemokines (MIP-2 and KC) and ICAM-1 were increased in the lung and heart by the ATRA administration. In immunohistochemical analyses, MIP-2 was clearly detected in alveolar macrophages of the lung in mice with RAS. Dexamethasone treatment prevented the development of RAS and decreased the CXC chemokine mRNA expression in the lung. These findings suggested that the activation of adhesion molecules for leukocytes and expression of CXC chemokines in the lung are closely involved in triggering RAS.
Introduction
All-trans retinoic acid (ATRA) significantly improves the outcome of patients with acute promyelocytic leukemia (APL). 1, 2 ATRA induces terminal differentiation 3 and cellular senescence 4 of APL cells followed by clinical remission. During treatment, however, 15-26% of patients develop 'retinoic acid syndrome (RAS)', [5] [6] [7] which can be fatal. Typical symptoms and signs of RAS are unexplained fever, respiratory distress, weight gain, interstitial pulmonary infiltrates, and pleural and pericardial effusions. 6, 7 RAS is not observed in APL patients with consolidation/maintenance therapy using ATRA, but sometimes observed during arsenic trioxide therapy for APL. 8 In both cases, hyperleukocytosis of differentiated APL cells during therapy is likely associated with RAS. 7 In addition, administration of G-CSF or hyperleukocytosis in myeloid leukemia is associated with adult acute respiratory distress syndrome, which has an indistinguishable clinical presentation from RAS. 9, 10 Therefore, differentiated and activated granulocytes are speculated to have a key role in RAS.
Several mechanisms have been proposed to explain RAS. First, the surface expression of CD11b, CD11c and CD54 (ICAM-1) increases in ATRA-treated APL cells. [11] [12] [13] ATRA thus activates interaction between b 2 -integrins (CD11/CD18 heterodimer) and ICAM-1, promoting the adherence and leukoaggregation of APL cells. 11 Second, differentiated APL cells contain several mediators of lung damage, including cathepsin G and serine protease, which enhance capillary permeability.
14 An APL cell line, NB4, constitutively secretes the matrix metalloproteases MMP-9 and MMP-2, which promote cellular invasion via degradation of the extracellular matrix. 15 ATRA treatment also upregulates the expression of urokinase and plasminogen activator in NB4 cells. 16 Third, inflammatory cytokines such as interleukin (IL)-1b, G-CSF, IL-8 and TNF-a are secreted from APL cells treated with ATRA, [17] [18] [19] and might be associated with RAS. However, it is unknown whether RAS is directly mediated by the differentiated APL cells, whether the differentiated APL cells are sufficient for RAS to develop, and why the lung is mainly targeted in RAS. To answer these questions, an animal model of RAS is required. Previously, we generated a murine APL model xenotransplanted with an APL cell line, NB4. 20 Here we show that the injection of fully differentiated NB4 cells into immunodeficient mice followed by administration of ATRA shortened the survival of the mice, and the pathological findings were similar to RAS. We analyzed the necessary conditions for RAS, and found the involvement of CXC chemokines and adhesion molecules in the lung following the ATRA administration.
Materials and methods

Cell lines
The APL cell line NB4 and its ATRA-resistant subline NB4/RA were used in this study. 12 The cells were grown in RPMI 1640 medium (Gibco-BRL, Gaithersburg, ND, USA) with 10% fetal calf serum (Gibco-BRL) containing 2 mmol/l of L-glutamine, 100 IU/ml of penicillin (Meiji Seika, Japan) and 100 mg/ml of streptomycin (Meiji Seika). The cells were treated with 1 mM of ATRA (Sigma, MO, USA) for 6 days and differentiation was morphologically confirmed using cytospin specimens. After a wash with phosphate-buffered saline, the cells were used for injection. In one experiment, the phenotypes of ATRA-treated NB4 cells were CD11b
, whereas those of untreated NB4 cells were CD11b
Mice and in vivo treatment
NOD/Shi-scid/scid (NOD/scid) and C57BL/6 mice were purchased from CLEA Japan (Japan). NOD/scid/gc À/À mice, NOD/ scid mice with IL-2Rgc À/À , developed by crossing NOD/Shi-scid mice with C57BL/6J-gc À/À mice as described, 21 were maintained at the Central Institute for Experimental Animals (Japan). ATRA-treated NB4 cells (1 Â 10 5 , 1Â 10 6 or 1 Â 10 7 ) were intravenously injected into 7-to 8-week-old male mice via a tail vein, and then 100 ml of ATRA (1 mg/ml) was administered orally for 6 consecutive days. The animal experiments were performed according to the guidelines of the Institute for Laboratory Animal Research, Nagoya University School of Medicine, and were approved by the institutional ethics committee for laboratory animals used in experimental research.
Evaluation of pulmonary edema and pathological examination
On day 6 after the injection of NB4 cells, mice were killed and organs were extracted. The wet lung weight/total body weight (L/T) ratio was calculated as an indicator of pulmonary edema or congestion. The L/T ratios in mice from the experimental and control groups were compared using Student's t-test. To evaluate morphological status, the extracted tissues were fixed with 10% formalin, and 4-mm sections mounted on slides were stained with hematoxylin and eosin. For immunohistochemical staining of human CD45, an LSAB2 system (DAKO Japan, Japan) was employed according to the instructions supplied. For immunohistochemical staining of mouse MIP-2, we used antimouse MIP-2 rabbit antibody (Monosan, The Netherlands) and peroxidase-conjugated anti-rabbit goat antibody (Rockland, PA, USA), developed using DAB (Sigma, MO, USA). All sections were counterstained with hematoxylin.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared from mouse organs using a QIAamp RNA Blood Mini kit (Quiagen, Chatsworth, CA, USA) following the manufacturer's instructions. cDNA was synthesized from the RNA using a random primer, dNTP, Superscript II (reverse transcriptase, Gibco-BRL), dithiothreitol and MgCl 2 in a final volume of 20 ml at 421C for 40 min. The cDNAs of mouse MIP-2, KC, ICAM-1, LIX and b-actin were amplified with dNTP, Ampli taq Gold (DNA polymerase, Perkin-Elmer, CT, USA) and 20 mM of the primers in 50 ml reaction volumes using a Gene Amp PCR System 9600 (Perkin-Elmer). The thermal cycles consisted of denaturation at 941C for 30 s, annealing at 601C for 90 s and polymerization at 721C for 120 s. In all, 35 cycles were performed for MIP-2, KC and b-actin, and 25 or 35 cycles for ICAM-1. The primers for MIP-2, KC, ICAM-1, LIX and b-actin were synthesized by Nihon Gene Research Lab's (Japan), and these sequences were as follows: b-actin sense primer, 0 -CCGTTCTTTCCACTGCGAGTGC-3 0 (257 bp). 24 PCR products were separated on 1.5% agarose gels and visualized by ethidium bromide staining and photographed on a UV transilluminator FAS III (TOYOBO, Japan).
Therapeutic model for prevention of RAS
The ATRA-treated NB4 cells (1 Â 10 7 ) were intravenously injected into NOD/scid mice via the tail vein, and 100 ml of ATRA (1 mg/ml) was orally administered and 50 mg of dexamethasone (Sigma, MO, USA) was subcutaneously injected for 6 consecutive days. On day 6 after the injection of NB4 cells, mice were killed and organs were extracted. The L/T ratios in mice from the experimental and control groups were compared using Student's t-test.
Results
Injection of differentiated NB4 cells followed by ATRA administration caused early death in NOD/scid mice In 12 mice injected with ATRA-treated NB4 cells, oral intubation of ATRA was started on the day of injection and continued for 6 consecutive days. Unexpectedly, three mice died on day 3, 5 and 14. The autopsy revealed pulmonary effusion, congestive lungs and ascites ( Figure 1 ). Histopathologically, ATRA-treated mice showed marked congestive changes in the lungs. The alveolar septum was edematous containing numerous erythrocytes and small round inflammatory cells. The thickened alveolar capillary contained a clouded serum element with platelet aggregation. Alveoli were occasionally filled with Figure 1 Pathological findings of RAS in mice. Upper: NOD/scid mouse treated with an intravenous injection of 1 Â 10 7 ATRA-treated NB4 cells followed by oral administrations of 100 mg of ATRA for 6 consecutive days. Lower: NOD/scid mouse treated with an intravenous injection of 1 Â 10 7 untreated NB4 cells. Mice were killed 6 days after the injection. Lung sections stained with hematoxylin and eosin. Original magnification: Â 400.
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Necessary conditions for RAS in NOD/scid mice
To clarify the conditions necessary for RAS, the wet lung weight/ total body weight (L/T) ratio on day 6 was measured as an indicator of lung edema. Mice injected with ATRA-treated NB4 cells and orally administered with ATRA had an increased L/T ratio compared to mice injected with untreated NB4 cells and orally administered with ATRA as a control (P ¼ 0.05). The mice given ATRA-treated NB4/RA cells (ATRA-resistant NB4) followed by ATRA showed no increase in the L/T ratio compared to the control mice (P ¼ 0.09) (Figure 2a ). The injected cell number was associated with the cause of RAS. The dose response of ATRA-treated NB4 cells was examined. The injection of 10 5 or 10 6 cells did not significantly change the L/T ratio, indicating that 10 7 cells are necessary to induce RAS (Figure 2b ). The route of injection of NB4 cells was also associated with the L/T ratio. Intravenous injection of ATRA-treated NB4 cells significantly increased the L/T ratio (P ¼ 0.01). However, intraperitoneal (P ¼ 0.26) or subcutaneous injection (P ¼ 0.06) of ATRA-treated NB4 cells did not produce a significant change (Figure 2c ). These findings suggest that intravenous injection of a sufficient number ( 10 7 ) of ATRA-treated NB4 cells was necessary to cause RAS in NOD/scid mice.
To study the effects of genetic background on RAS, we used C57BL/6 and NOD/scid/gc À/À mice in addition to NOD/scid mice. The L/T ratio of NOD/scid/gc À/À mice increased significantly on combined intravenous injection of ATRA-treated NB4 cells and administration of ATRA (P ¼ 0.04), compared to the control mice. That of NOD/scid mice (P ¼ 0.09) and C57BL/ 6 mice (P ¼ 0.10) increased slightly compared to the controls (Figure 3) . Importantly, oral administration of ATRA was necessary for the increase (Figure 3 ). This result was consistent with the finding that oral administration of ATRA caused early death in mice injected with ATRA-treated NB4 cells. NOD/scid mice have impaired T-cell, B-cell and complement functions, and NOD/scid/gc À/À mice additionally lack NK functions. 21 Accordingly, the increase in the L/T ratio was not related to the anti-human response induced by mouse lymphocytes but to the inflammatory response caused by ATRA-treated NB4 cells and the administration of ATRA.
Direct association between NB4 cells and lung damage
Since the above findings strongly suggested that the differentiated NB4 cells directly damage murine lung, we examined whether NB4 cells accumulated after the injection. At 2 days after the injection of ATRA-treated NB4 cells, NB4 cells, as CD45-positive cells, were detectable in the lungs of mice administered ATRA. However, they were undetectable in the lungs of mice not given ATRA (Figure 4a & b) . On day 6, NB4 cells were rarely found in the lung (data not shown) but were present in the pleural effusion (Figure 4c ), suggesting their extravasation.
Increased expression of inflammatory chemokines and ICAM-1 in the lung
To study the effect of ATRA on the lung, we examined the expression of inflammatory chemokines and adhesion molecules after the ATRA administration. Among chemokine receptors, the IL-8 receptor is essential for the chemotaxis of granulocytes and differentiated APL cells. Since mice have no clearcut homolog of IL-8, we examined the expression of MIP-2 and KC. MIP-2 and KC are known to be functionally active toward the IL-8 receptor.
25,26 MIP-2 mRNA expression was clearly detected in the lung, heart and spleen of mice administered ATRA, whereas it was detected only slightly in the liver and large intestine in the control mice ( Figure 5 ). KC mRNA expression was upregulated in the heart, lung, spleen, stomach and muscle compared to the control mice. Expression of ICAM-1 mRNA was augmented in the heart and lung after ATRA administration; however, it was not detected in the control mice ( Figure 5 ).
Increased expression of MIP-2 in the lung detected by immunohistochemical analyses
In the lung from mice with RAS, MIP-2 was detected in alveolar macrophages ( Figure 6 ). Infiltrating ATRA-treated NB4 cells were also stained, as we used anti-mouse MIP-2 rabbit polyclonal antibody, which was thought to crossreact with human CXC chemokine. In the lung from control mice, no MIP-2-positive cells were observed.
Therapeutic model for prevention of RAS
We used this RAS model for therapeutic evaluation of the subcutaneous injection of 50 mg of dexamethasone. The L/T ratio of mice from the therapeutic group was suppressed significantly compared to that of RAS model mice (P ¼ 0.03). The L/T ratio of the mice was the same as that of the controls (P ¼ 0.44) (Figure 7 ). This result showed that RAS could be prevented by the subcutaneous injection of dexamethasone.
Decreased expression of CXC chemokines and cell adhesion molecule mRNA in the lung following dexamethasone treatment
To study the mechanism of the prevention of RAS by dexamethasone, the mRNA expression of LIX, MIP-2, KC and ICAM-1 was determined by RT-PCR. LIX is a CXC chemokine and a homolog of human CXCL5 (ENA-78), and its expression was reported to be suppressed by dexamethasone treatment. 27 Accordingly, LIX expression was measured as a control. The expression of LIX and MIP-2 in the lung was clearly suppressed by dexamethasone. However, the expression of KC and ICAM-1 mRNA was only slightly changed ( Figure 8 ). These results indicate that dexamethasone administration prevents pulmonary edema and congestion by inhibiting the expression of CXC ATRA-treated NB4 cells and then administered 100 mg of ATRA for 6 days. Mice were killed 6 days after the injection. Original magnification: Â 1000.
Retinoic acid syndrome in NOD/scid mice M Ninomiya et al chemokines and adhesion molecules in the lung. The extent to which RAS was induced was evaluated based on the L/T ratio and histological examination. The increase in the L/T ratio and histological findings related to the upregulation of CXC chemokine and ICAM-1 mRNA expression (data not shown).
Discussion
In this study, we generated an animal model of RAS by injecting ATRA-treated NB4 cells and then administering ATRA into NOD/scid mice to clarify the necessary conditions for, and molecular mechanism causing, RAS. The main factors for NB4 cells were full differentiation, cell number and route of injection. On histological examination, NB4 cells were found to accumulate in the lung for 2-3 days after the injection and then to be extravasated into the pleural effusion. The pathophy- Expression of MIP-2, KC and ICAM-1 mRNA in various organs of the NOD/scid mouse following oral intubation with 100 mg of ATRA for 5 days. Lane 1: kidney; 2: heart; 3: lung; 4: brain; 5: bone marrow; 6: spleen; 7: small intestine; 8: large intestine; 9: liver; 10: stomach; 11: muscle. ATRA-treated NB4 cells into NOD/scid mice, combined oral intubation of 100 mg of ATRA and subcutaneous injection of 50 mg of dexamethasone were performed daily for 6 days.
Retinoic acid syndrome in NOD/scid mice M Ninomiya et al siology of this model closely resembles the pulmonary histology of RAS patients: edema, fibrous exdates and leukocytes in the alveolar air space. 6 These findings confirm that differentiated APL cells are directly involved in RAS. On the basis of autopsy findings, De Botton et al 7 described that an insult to the pulmonary endothelium was important in the pathogenesis of RAS, although the mechanism involved remains unknown. Our data showed a direct role by differentiated APL cells.
In this study, systemic administration of ATRA was also necessary for RAS. We thus speculated that ATRA increases chemokine production and causes differentiated APL cells to collect in the lung. This idea was supported by reports that IL-8 was transcriptionally upregulated by ATRA in cultured human or monkey bronchial epithelium. 28, 29 MIP-2 and KC compensate for IL-8 in mice, 30 and function on human neutrophils through the chemokine receptor IL-8R. 25, 26 We showed that MIP-2 and KC mRNAs were readily transcribed in the lung, heart and spleen after administration of ATRA. Additionally, secretion of IL-8 and activation of b 2 -integrins have been reported in NB4 treated with ATRA. 31, 32 Furthermore, IL-8R expression is upregulated along with myeloid differentiation. Taken together, the interaction between IL-8 and IL-8R might be significantly involved in the initiation and progression of human RAS.
Since in APL cells the expression of integrin family members increases during differentiation, we studied the expression of the ligands of this family (ICAM-1). ICAM-1 mRNA expression was enhanced in the lung and heart of RAS model mice. The specific expression of ICAM-1 in these tissues is quite important to RAS. In immunohistochemical examinations, ICAM-1 was weakly expressed in endothelial cells of lung tissue. Septic lung tissue presents strong staining of ICAM-1. 33 Various proinflammatory cytokines are believed to activate the increased expression of adhesion molecules. 34 On the other hand, ATRA treatment enhanced b 2 -integrin expression in an APL cell line. 35, 36 So the particular tissue damage in the lung was thought to be the result of adherence followed by interaction with the ICAM-1 molecule on the alveolar capillary endothelial cells and b 2 -integrin molecule on the APL cells. The adhered APL cells might be extravasated into the alveolar interstitum in a process accelerated by the upregulation of CXC chemokines (MIP-2 and KC) in the alveolar macrophages.
For the treatment of RAS, only steroids are currently available. 37 In this study, we administered dexamethasone to mice. The results imply novel preventive approaches to RAS, and mRNA levels revealed that the LIX and MIP-2 expressions were completely inhibited by the dexamethasone injection. KC or ICAM-1 expression was slightly downregulated by the treatment. In general, leukocyte migration proceeds via the following process: (1) rolling on vascular endothelial cells, (2) tight adherence to the vascular endothelial cells and (3) extravasation into the alveolar interstitum. Cell adhesion molecules and chemokines participate in each stage. A possible preventive strategy is to block the interactions between adhesion molecules (b 2 -integrin) expressed on differentiated APL cells and the counter-receptor (ICAM-1) on the endothelium. Antibodies or statins that inhibit ICAM-1 or its ligand might be promising. 14, 38, 39 Another approach is to inhibit the activation of CXC chemokines by using chemokine receptor antagonists that have been developed to inhibit chemokine responses. 40, 41 It was also reported that acute respiratory distress syndrome caused by radiation was prevented by the use of anti-IL-8 antibody. 42, 43 In conclusion, these findings suggest that intravenous injection of a sufficient number (10 7 ) of fully differentiated NB4 cells was necessary to cause RAS in NOD/scid mice. Administration of ATRA was also necessary. The gene expression levels of CXC chemokines and ICAM-1 were increased by ATRA administration in the lung and heart. Dexamethasone treatment prevented the development of RAS and decreased the CXC chemokine and ICAM-1 mRNA expression in the lung. Hence, the blocking of CXC chemokines and ICAM-1 is suggested to be a primary approach to the prevention of RAS.
